In this article, we will discuss Olaparib (Description-20). So, let’s get started.
SOLO-1 demonstrated a statistically significant improvement in investigator-assessed PFS for Olaparib compared to placebo. Results from a blinded independent review were consistent. At the time of the analysis of PFS, overall survival (OS) data were not mature (21% of patients had died).